ILMN · earnings call history
Illumina Q2 FY26 — Strong Clinical Demand Drives Raised Full-Year Guidance
Read the briefIllumina Q1 FY26 — Strong Clinical Growth and NovaSeq X Demand Drive Raised Outlook
Read the briefIllumina Q4 FY25 — Clinical Consumables Drive Strong Performance
Read the briefIllumina Q3 FY25 — Strong Clinical Growth and NovaSeq X Transition
Read the briefIllumina Q2 FY25 — Strong Clinical Demand and Raised FY25 Guidance
Read the briefIllumina Q1 FY25 — NovaSeq X Momentum and Strategic Cost Actions
Read the briefIllumina Q4 FY24 — NovaSeq X Transition Drives Revenue Growth and Margin Expansion
Read the briefBrowse all US companies on the earnings-call register.